BC Week In Review | Dec 14, 2015
Clinical News

PAN-90806: Preliminary Phase I/II data

Preliminary data from stage 1 of the open-label, U.S. Phase I PAN-01-101 trial in 40 treatment-naive patients with wet AMD showed that all dose levels of once-daily topical PAN-90806 ophthalmic solution for up to 8...
BC Week In Review | Apr 21, 2014
Clinical News

PAN-90806: Phase I started

PanOptica began a 2-month, open-label, U.S. Phase I trial to evaluate 3 dose levels of topical ocular PAN-90806 daily in about 30 patients with active, subfoveal choroidal neovascularization associated with wet AMD. PanOptica has exclusive,...
BC Extra | Apr 15, 2014
Top Story

PanOptica secures $45 million in series B

Ophthalmology play PanOptica Inc. (Mount Arlington, N.J.) secured $45 million in a tranched series B round co-led by new investor Novo Ventures and existing investor Third Rock Ventures. Existing investor SV Life Sciences also participated....
BC Week In Review | Jan 10, 2011
Company News

PanOptica, Astellas deal

Astellas' OSI Pharmaceuticals Inc. subsidiary granted PanOptica exclusive, worldwide rights to develop and commercialize PAN-90806 for ophthalmic indications. The small molecule selective inhibitor of VEGF was previously in Phase II testing for late-stage cancer by...
BioCentury | Jan 10, 2011
Emerging Company Profile

PanOptica: Dropping in on VEGF

Most of the next generation of treatments for age-related macular degeneration are focusing on reducing or eliminating intravitreal injections, which are burdensome to patients and present safety risks. PanOptica Inc. believes its PAN-90806 , a small...
BC Extra | Jan 5, 2011
Company News

PanOptica raises $30M, in-licenses ophthalmic compound

PanOptica Inc. (Mount Arlington, N.J.) raised $30 million in a series A round and in-licensed exclusive, worldwide rights to PAN-90806 from OSI Pharmaceuticals Inc. for ophthalmic indications. The small-molecule selective inhibitor of VEGF is in...
Items per page:
1 - 6 of 6